drugset / Trial / NCT06249165

VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease

NCT06249165

Phase 4 Active not recruiting 130 enrolled Duke University Novartis Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

VictORION-INCLUSION (V-INCLUSION) seeks to evaluate the effectiveness of inclisiran as an innovative therapy with the potential to help bridge care gaps in historically understudied and undertreated populations by leveraging electronic health records (EHR) in multiple US Healthcare Systems (HCS) to systematically identify those at high risk for and already diagnosed with ASCVD for more expeditious achievement of LDL-C targets.

Timeline

Start
2024-12-16
Primary completion
2026-12
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Inclisiran Small interfering RNA (siRNA) 284 mg